IASO206 in Patients With Relapsed/Refractory Multiple Myeloma

Inclusion Criteria: * 18 to 75 years old, male or female; * Diagnosed with relapsed/refractory multiple myeloma (RRMM) according to IMWG criteria, and have received at least 2 lines of treatment including one proteasome inhibitor and one immunomodulator; with documented disease progression (based on examination data) during or within 12 months after the latest anti-myeloma treatment (subjects whose last-line treatment was CAR-T therapy are not required to have progression within 12 months); * Presence of measurable lesions during screening according to any of the following criteria: * Serum monoclonal protein (M-protein) level: ≥5 g/L f； * Urine M protein level ≥200 mg/24 hours; * Light chain multiple myeloma without measurable lesions in serum or urine: the affected serum free light chain ≥100 mg/L with abnormal serum κ/λ free light chain ratio; * BCMA expression on MM cells determined by flow cytometry or pathology immunohistochemistry; * ECOG score ≤ 2; * Expected survival time ≥12 weeks; * Subjects must have adequate organ function: * Hematology: Absolute neutrophil count (ANC) ≥ 1×10\^9/L (supportive treatment within 7 days before laboratory test is not allowed); Absolute lymphocyte count (ALC) )≥0.3×10\^9/L; platelets≥50×10\^9/L (blood transfusion support within 7 days before laboratory test is not allowed); hemoglobin ≥60 g/L (without red blood cell \[RBC\] transfusion within 7 days before laboratory test); * Liver function: Alanine aminotransferase (ALT) an…